Best AI Index Fund to Buy
Over the last two years, companies with a focus on…
Buy
52
ARZGY Quote, Financials, Valuation and Earnings
Last price:
$18.19
Seasonality move
:
0.34%
Day range:
$18.07 - $18.22
52-week range:
$11.83 - $19.78
Dividend yield:
4.45%
P/E ratio:
14.47x
P/S ratio:
0.65x
P/B ratio:
1.74x
Volume:
18.3K
Avg. volume:
24.1K
1-year change:
43.34%
Market cap:
$55B
Revenue:
$64.6B
EPS (TTM):
$1.30
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Generali has -- downside to fair value with a price target of -- per share.
ARZGY vs. S&P 500
-
Over the past 5 trading days, Generali has underperformed the S&P 500 by -5.08% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Generali does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Generali has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Generali reported revenues of --.
Earnings Growth
-
Generali earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Generali reported earnings per share of $0.72.
Enterprise value:
-180.2B
EV / Invested capital:
--
Price / LTM sales:
0.65x
EV / EBIT:
-46.41x
EV / Revenue:
-2.10x
PEG ratio (5yr expected):
0.63x
EV / Free cash flow:
-3.78x
Price / Operating cash flow:
3.60x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
0.72%
Net Income Margin (TTM):
5.07%
Return On Equity:
11.6%
Return On Invested Capital:
8.19%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | $0.67 | $0.72 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $445.6B | $426.8B | $255.8B | $266.1B | $267B | |
| Total Assets | $670B | $663.7B | $539.7B | $562.2B | $560.5B | |
| Current Liabilities | $18.4B | $17.4B | $10B | $11.8B | $12.1B | |
| Total Liabilities | $630.9B | $627.6B | $508.6B | $527.6B | $526.1B | |
| Total Equity | $39.1B | $36.1B | $31.1B | $34.6B | $34.4B | |
| Total Debt | -- | $18.8B | -- | -- | $18.3B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2014-06-30 | 2015-06-30 | 2016-06-30 | 2015-06-30 | 2016-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | $11B | $15.7B | |
| Cash From Investing | -- | -- | -- | -$10.6B | -$12.6B | |
| Cash From Financing | -- | -- | -- | -$1.6B | -$4.4B | |
| Free Cash Flow | $38.6B | $39.8B | $47.7B | $10.8B | $15.6B | |
ARZGY
Sector
Market Cap
$55B
$608.2M
Price % of 52-Week High
91.96%
87%
Dividend Yield
4.45%
2.03%
Shareholder Yield
--
4.07%
1-Year Price Total Return
43.34%
10.08%
Beta (5-Year)
1.023
0.587
Dividend yield:
4.45%
Annualized payout:
$0.69
Payout ratio:
53.25%
Growth streak:
2 years
Technicals
8-day SMA
Sell
Level
$18.61
200-day SMA
Buy
Level
$15.52
Bollinger Bands (100)
Buy
Level
15.68 - 18.48
Chaikin Money Flow
Buy
Level
2.8M
20-day SMA
Sell
Level
$19.01
Relative Strength Index (RSI14)
Sell
Level
42.55
ADX Line
Sell
Level
18.07
Williams %R
Buy
Level
-92.9866
50-day SMA
Buy
Level
$18.07
MACD (12, 26)
Buy
Level
0.10
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
66.3K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.7655)
Sell
CA Score
(Annual)
Level (-2.3935)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (0.0485)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
The roots of Generali date back to the 1830s and the Bora wind and rough seas that hit the Trieste region. Over that decade Generali sought to expand throughout Italy, but this growth was held back by the fragmented nature of Italy. The Italian Revolution in the 1840s paved the way for easier expansion in the country. After World War I, Trieste was handed back to Italy. The dissolution of the Austro-Hungarian Empire created a fragmented Europe and a fragmented Generali. While to this day Generali remains quite a diversified company, its core operations remain in historical Austro-Hungarian countries of Austria, Central and Eastern Europe, Germany, and Italy. This is the case in Generali’s nonlife business and France is also an important contributor to life and savings.
Stock Forecast FAQ
In the current month, ARZGY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ARZGY average analyst price target in the past 3 months is --.
-
Where Will Generali Stock Be In 1 Year?
According to analysts, the consensus estimate is that Generali share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Generali?
Analysts are divided on their view about Generali share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Generali is a Sell and believe this share price will rise from its current level to --.
-
What Is Generali's Price Target?
The price target for Generali over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ARZGY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Generali is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of ARZGY?
You can purchase shares of Generali via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Generali shares.
-
What Is The Generali Share Price Today?
Generali was last trading at $18.19 per share. This represents the most recent stock quote for Generali. Yesterday, Generali closed at $18.19 per share.
-
How To Buy Generali Stock Online?
In order to purchase Generali stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Salesforce Stock Be in 5 Years?
Salesforce (NYSE: CRM) just turned in a quarter that, on…
2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for May 31
Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.
Buy
55
RGC alert for May 31
Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.
Sell
42
AMBA alert for May 31
Ambarella [AMBA] is down 15.13% over the past day.
